Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced that the U.S. Food and Drug ...

Rami Komrokji, M.D.: I think ET (essential thrombocythemia) and PV (polycythemia vera) are similar but myelofibrosis probably is a little bit different, so the spectrum of symptoms and the goals of ...

Dr. Prithviraj Bose explains how doctors tailor myelofibrosis treatments and how patients can work with their care teams to navigate options. The discovery of the JAK2 gene mutation marked a turning ...

Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with ...

LONDON--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk ...

New translational data suggests potential disease-modifying effects following treatment with pelabresib of both first-line and ruxolitinib-relapsed/refractory ...

Please provide your email address to receive an email when new articles are posted on . Amanam, an assistant professor in the Division of Leukemia at City of Hope Cancer Center, highlighted a study ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. In terms of treatment options that are ...

CAMBRIDGE, Mass., June 8, 2022 /PRNewswire/ -- Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today announced the U.S. Food Drug and Administration (FDA ...